Your browser doesn't support javascript.
loading
Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension.
Oxlund, C S; Cangemi, C; Henriksen, J E; Jacobsen, I A; Gram, J; Schousboe, K; Tarnow, L; Argraves, W S; Rasmussen, L M.
Afiliação
  • Oxlund CS; 1] Research Unit for Cardiovascular and Metabolic Prevention, Department of Endocrinology, Odense University Hospital, Odense C, Denmark [2] Centre for individualized Medicine in Arterial Diseases, Odense University Hospital, Odense C, Denmark.
  • Cangemi C; 1] Centre for individualized Medicine in Arterial Diseases, Odense University Hospital, Odense C, Denmark [2] Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense C, Denmark.
  • Henriksen JE; Research Unit for Cardiovascular and Metabolic Prevention, Department of Endocrinology, Odense University Hospital, Odense C, Denmark.
  • Jacobsen IA; Research Unit for Cardiovascular and Metabolic Prevention, Department of Endocrinology, Odense University Hospital, Odense C, Denmark.
  • Gram J; Department of Endocrinology, Esbjerg, Denmark.
  • Schousboe K; Department of Medicine, Fredericia, Denmark.
  • Tarnow L; Steno Diabetes Centre, Gentofte, Denmark.
  • Argraves WS; Department of Regenerative Medicine and Cell Biology, Medical University of South Carolina, Charleston, SC, USA.
  • Rasmussen LM; 1] Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense C, Denmark [2] Department of Endocrinology, Esbjerg, Denmark.
J Hum Hypertens ; 29(1): 28-32, 2015 Jan.
Article em En | MEDLINE | ID: mdl-24739800

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espironolactona / Pressão Sanguínea / Proteínas de Ligação ao Cálcio / Diabetes Mellitus Tipo 2 / Diuréticos / Antagonistas de Receptores de Mineralocorticoides / Hipertensão / Anti-Hipertensivos Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Espironolactona / Pressão Sanguínea / Proteínas de Ligação ao Cálcio / Diabetes Mellitus Tipo 2 / Diuréticos / Antagonistas de Receptores de Mineralocorticoides / Hipertensão / Anti-Hipertensivos Idioma: En Ano de publicação: 2015 Tipo de documento: Article